Skip to main content

Table 3 Antimicrobial susceptibility of isolates of Enterobacter species and Escherichia coli

From: Erratum to: Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study

Antimicrobiala

Enterobacter SBP

(n = 31)

E. coli SBP

(n = 125)

P

Cefotaxime

23/31 (74.2)

106/125 (84.8)

0.16

Ceftazidime

22/31 (71.0)

106/125 (84.8)

0.07

Ceftriaxone

22/31 (71.0)

106/125 (84.8)

0.07

Third-generation cephalosporinsb

22/31 (71.0)

106/125 (84.8)

0.07

Cefepime

25/29 (86.2)

103/123 (83.7)

1.00

Ciprofloxacin

25/31 (80.6)

76/125 (60.8)

0.038

Piperacillin/tazobactam

23/31 (74.2)

116/125 (92.8)

0.003

Imipenem

31/31 (100.0)

125/125 (100.0)

1.00

Trimethoprim-sulfamethoxazole

27/31 (87.1)

74/125 (59.2)

0.003

Amikacin

30/31 (96.8)

124/125 (99.2)

0.36

Gentamicin

27/31 (87.1)

84/125 (67.2)

0.03

Tobramycin

27/31 (87.1)

81/125 (64.8)

0.02

  1. Values are n (%) unless otherwise indicated
  2. aNot all of the isolates underwent susceptibility testing
  3. bMeans cefotaxime or ceftriaxone. The susceptibility to third-generation cephalosporins was defined by the breakpoints of the 2008 Clinical Laboratory Standards Institute guidelines (susceptible, ≤ 8 μg/ml; intermediate, 16–32 μg/ml; and resistant, ≥ 64 μg/ml) [18]